EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research ...
One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
Pace Analytical Services, Inc. Is Pleased To Announce The
Launch Of Its New And Improved Website. The
New Site Provides Users With A Comprehensive Overview Of Pace Analytical And Incorporates A More User-Friendly Design Layout To Enhance Functionality And Navigation. The
Site Also Offers An Expan...
Transposagen Creates a Rat Model of the Human Immune System
LEXINGTON, Ky. , Aug. 6 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. based in Lexington, KY announced today that its scientists and collaborators from the
Medical College of Wisconsin have created and characterized the
world's first rat model of severe combined immunodefi...
PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago
"Finding a needle in a haystack - 4 molecules out of a million"
NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/
-- Curis, Inc. (NASDAQ: CRIS ), a drug development company focused on
developing proprietary targeted medicines for cancer treatment and Debiopharm
Group (Debiopharm), a group of companies with a focus on the
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today announced its financial results for the
second quarter ended June 30, 2009.
"We were pleased to observe continued sales growth in our Proprietary Medical Products business during the
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
SEATTLE, Aug. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent achievements and financial results for the
second quarter and six months ended June 30, 2009.
"The second quarter of 2009 was a transforming quarter for the
CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform
CARLISLE, Mass., Aug. 5 /PRNewswire/ -- CapitalBio Corporation and VigeneTech Inc. have announced the
launch of a fully integrated microarray solution platform. CapitalBio Corp., a developer and marketer of diagnostic biochips and advanced microarray instrument systems, in collaboration with ...
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
BETHESDA, Md. and BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Today, the
Foundation for the
National Institutes of Health and sanofi-aventis announced an unprecedented donation by the
global pharmaceutical leader providing approximately $1.3 million in pharmaceutical th...
Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient
ASL Pharmacy® announces the
availability of Compounded Mupirocin Liquid. Mupirocin is typically only found in ointment form. ASL's compound does not contain any added ingredients, only pure mupirocin, sterile water and sterile saline. This is significant because ASL serves patients with chron...
Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
JERUSALEM, Israel, August 4 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer
of oral delivery systems, today reported that its wholly owned Israeli
subsidiary, Oramed Ltd., was awarded a government grant amounting to a total
Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the
development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the
VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS ), a pharmaceutical company dedicated to the
development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the
Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) is scheduled to present at the
Canaccord Adams 29th Annual Global Growth Conference at the
Intercontinental Hotel in Boston on August 13, 2009, 2:00 p.m. Eastern Time.
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the
Company), a late-stage biopharmaceutical company, announced today that the
Office of Orphan Products Development of the
United States Food and Drug Administration (FDA) has granted Or...
AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosi...
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
STAMFORD, Conn. and PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced entry into an exclusive license and collaboration agreement to commercialize Intermezzo ((R)) (z...
Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) is scheduled to present at the
upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the
Millennium Broadway Hotel in New York City on Wednesday, August 5, 2009 at 1:45 p.m. ...
Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the
second quarter ended June 30, 2009 on Tuesday, August 4, 2009, after the
close of U.S.-based financial markets. Howard Robin, president and chief execut...
SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
RALEIGH, N.C. , July 30 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for the
management and analysis of genetic data, today announced that it has entered into an agreement under which The
Johns Hopkins Hospital will utilize SmartGene's advanced technology and integrated...
Sunesis Receives Approval for Listing on The NASDAQ Capital Market
SOUTH SAN FRANCISCO, Calif., July 30 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for the
treatment of solid and hematologic cancers, today announced th...
Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
PITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced its financial results for the
three and six months ended June 30, 2009.
Adjusted diluted EPS, which excludes the
impact of certain purchase acc...
"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila
TOKYO, July 30 /PRNewswire/ -- With a business plan to launch 8-10 new
products each year, Nippon Universal Pharmaceutical Co. Ltd., a subsidiary of
the Zydus group, one of India's leading integrated pharma companies & a
global healthcare provider, is looking to give a big boost to its ope...
NIST scientists study how to stack the deck for organic solar power
A new class of economically viable solar power cellscheap, flexible and easy to makehas come a step closer to reality as a result of recent work* at the
National Institute of Standards and Technology (NIST), where scientists have deepened their understanding of the
complex organic films at the
BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- BP and Verenium Corporation (Nasdaq: VRNM ) today announced that its 50-50 joint venture company will operate under the
name Vercipia Biofuels, and plan to relocate its corporate headquarters to Florida. Vercipia continues to foc...
Sunesis Reports Financial Results for the Second Quarter 2009
SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today reported financial results for the
second quarter ended June 30, 2009.
Total revenue for the
second quarter of 2009 was $3.5 million, with a net loss of $22.9 ...
United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients
SUNRISE, Fla., July 28 /PRNewswire-FirstCall/ -- Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today that the
US FDA cleared a p...
GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles
Basketball Great Shaquille O'Neal, Green Celebrities and
Other Investors to Attend July 30 Debut
Los Angeles, CA (Vocus) - GreenHouse announced today that on July 30, 2009 it will introduce the
revolutionary E-Fuel MicroFuelerTM, a portable in-home micro-refinery syste...
Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections
AUSTIN, Texas, July 27 /PRNewswire/ -- Patton Medical Devices, manufacturer of the
i-port(R) and a leader of injection port therapy, announced today that they have entered into a partnership agreement with Unomedical, a leading manufacturer of single use medical devices used in th...
PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
NES-ZIONA, Israel, July 24 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly Modigene Inc., today announced that it has entered into stock purchase agreements with private investors to sell up to $10 million of the
Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
MUMBAI, July 24 /PRNewswire/ --
- Frost & Sullivan's Food & Beverage Focus 2009 Annual Executive
MindXchange on Biotechnology Applications in the
Food & Beverage and Dietary
Indian food processing industry has seen some spectacular product
OMT announces a breakthrough in the development of a novel human antibody platform
Palo Alto, CA: July 23, 2009 Open Monoclonal Technology, Inc. (OMT), in collaboration with Sangamo BioSciences, Inc. (NASDAQ, SGMO), Sigma-Aldrich Corporation (NASDAQ: SIAL), The
Medical College of Wisconsin, and INSERM, today announced the
creation of the
first targeted knockout rats as detaile...
Genetically engineered bacteria compute the route
US researchers have created 'bacterial computers' with the
potential to solve complicated mathematics problems. The
findings of the
research, published in BioMed Central's open access Journal of Biological Engineering , demonstrate that computing in living cells is feasible, opening the
door to a...
Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
TUSTIN, Calif., July 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that senior management will present at the
Jesup & Lamont 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 at 8:30 am EDT at the
Boca Raton ...
Vistaar and the Professional Pricing Society Partner to Present Premier Symposium for Pricing Practitioners
Renowned pricing expert and industry thought leader Dr. Reed Holden to present the
Parsipany, NJ (PRWEB) July 22, 2009 -- Vistaar Technologies, Inc. Vistaar Technologies, a leading provider of pricing software for sales, marketing and finance groups, t...
Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
PASADENA, Calif., July 22 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE ), Landlord of Choice to the
Life Science Industry(R), announced today that an affiliate has entered into a long-term lease with Eli Lilly and Company as the
anchor tenant at the
Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook
PHILADELPHIA and LONDON, July 22 /PRNewswire/ -- The
2009 edition of the
trusted and often cited compendium of pharmaceutical research and development statistics, the
CMR International Pharmaceutical R&D Factbook , is now available. This year's Factbook offers extended cont...
University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
GOTHENBURG, Sweden, July 22 /PRNewswire/ -- Cellectricon, a leading
provider of cell-based screening solutions for research and drug discovery,
today announced its collaboration with University of Lodz, Poland. Under the
agreement University of Lodz invests in Cellaxess(R)HT, the
Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
SALT LAKE CITY, July 22 /PRNewswire/ -- Axial Biotech, Inc., a company personalizing spine care through the
development of molecular diagnostics, and the
University of Utah today announced that they have entered into a collaboration that allows Axial access to the
University's rich ...
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
PRINCETON, N.J. and SAN DIEGO, July 22 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the
treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and result...